Corruption Crackdown: Punjab Vigilance Bureau Arrests Drug Inspector for Pharma Bribery

Introduction to the Arrest

In a state where the fight against corruption remains a top priority, the Punjab Vigilance Bureau (VB) has once again demonstrated its resolve. On March 7, 2026, officials arrested Drug Inspector Ramandeep Gupta posted at the FDA Drug Wing in Sri Muktsar Sahib red-handed while accepting a bribe of ₹1 lakh. The case, stemming from a complaint by a Bathinda-based pharma manufacturer, underscores persistent issues of abuse of power in drug licensing and enforcement roles.

The Incident: How the Trap Was Laid

According to reports from the Punjab Vigilance Bureau and multiple credible sources, the complainant –a director of Radinex Life Sciences Private Limited, a Bathinda-based company manufacturing allopathic medicines since 2020 alleged that Inspector Gupta had raided and sealed his facility. The inspector reportedly demanded an ongoing bribe of ₹2 lakh per month to unseal the unit and allow operations to resume.

After failed negotiations, the complainant approached the Vigilance Bureau. Officials conducted a preliminary inquiry, verified the claims (including recorded conversations), and set up a trap. On the agreed date, the complainant handed over ₹1 lakh (as a negotiated installment) at a pre-arranged location on Mall Road in Bathinda. The VB team swooped in, catching Gupta in the act. He was immediately arrested, and a case was registered under the Prevention of Corruption Act.

Broader Context: Corruption in Pharma Regulation

Drug Inspectors play a critical role under the Drugs and Cosmetics Act, 1940. They inspect manufacturing units, ensure compliance with Good Manufacturing Practices (GMP), issue/renew licenses, and take action against violations like substandard drugs or illegal operations. However, this authority can sometimes lead to opportunities for rent seeking especially in a high stakes industry where delays or seals can cost companies dearly.

Punjab has seen several similar cases in recent years, but the state’s ongoing anti-corruption drive under the Vigilance Bureau has led to increased traps and arrests. This incident joins a string of actions against public servants demanding bribes for routine regulatory clearances. Such practices not only erode public trust but also risk compromising drug quality and safety if enforcement becomes transactional rather than merit-based.

Implications for the Pharma Industry and Public Health

For legitimate manufacturers, extortionate demands create unfair hurdles, discourage investment, and push some toward unethical shortcuts. For patients, any weakening of regulatory oversight can mean substandard or spurious medicines entering the market,a serious public health risk in a country already battling issues like counterfeit drugs.

The swift action by the VB sends a strong message: corruption in regulatory bodies will not be tolerated. It also highlights the importance of whistleblowers. The complainant’s courage in reporting the matter, combined with the VB’s efficient trap, shows that mechanisms exist to protect honest businesses.

Conclusion: Time for Systemic Reforms?

While individual arrests are welcome, they point to deeper systemic issues—low salaries relative to responsibilities, inadequate oversight of inspectors, and opaque licensing processes.

Strengthening digital tracking of inspections, mandatory body cams for field officers, faster grievance redressal, and higher penalties could reduce such incidents.

The arrest of Drug Inspector Ramandeep Gupta is a reminder that no position is above accountability. As Punjab pushes its “corruption-free” agenda, cases like this must lead to lasting reforms, ensuring the pharmaceutical regulatory system serves public health rather than personal gain.

What do you think? Have you encountered delays or irregularities in drug licensing processes?

Share your thoughts in the comments below.